title: Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III.
abstract: OBJECTIVE
  We studied bone marrow angiogenesis in different stages of multiple myeloma according to the Durie and Salmon classification and its correlations with other disease characteristics.
  
  
  METHODS
  Sixty-five immunohistochemical CD34-stained, paraffin-embedded bone marrow biopsies of multiple myeloma patients and 12 controls were studied. The mean number of microvessels per area in each sample was determined as the microvessel density (MVD). In addition, plasma cell infiltration of the bone marrow, serum beta2-microglobulin, immunoglobulin levels, C-reactive protein, and serum calcium concentration were measured in 22 patients with stage I multiple myeloma and in 43 patients in stage II-III.
  
  
  RESULTS
  In myeloma patients, the bone marrow MVD was significantly higher than in controls (P<0.001). In 43 patients with stage II-III multiple myeloma, MVD was significantly higher than in 22 patients with stage I (median MVD 46 and 21 vessels/mm(2), respectively, P=0.005). Additionally, in stage II-III the bone marrow MVD correlated positively with the bone marrow plasma cell infiltration (r=0.55, P<0.001) and the serum beta2-microglobulin level (r=0.53, P<0.001), while in stage I patients no correlation could be found.
  
  
  CONCLUSIONS
  Angiogenesis is significantly increased in stage II-III myeloma in comparison to stage I. In stages II-III, bone marrow angiogenesis is correlated with plasma cell infiltration and serum beta2-microglobulin levels.
authors.affiliation: Department of Oncology and Hematology, Universitätsklinikum Charité, Humboldt-Universität zu Berlin, 10098, Berlin, Germany.
authors.forename: Kathrin
authors.initials: K
authors.lastname: Niemöller
authors.forename: Christian
authors.initials: C
authors.lastname: Jakob
authors.forename: Ulrike
authors.initials: U
authors.lastname: Heider
authors.forename: Ivana
authors.initials: I
authors.lastname: Zavrski
authors.forename: Jan
authors.initials: J
authors.lastname: Eucker
authors.forename: Olaf
authors.initials: O
authors.lastname: Kaufmann
authors.forename: Kurt
authors.initials: K
authors.lastname: Possinger
authors.forename: Orhan
authors.initials: O
authors.lastname: Sezer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001853:Bone Marrow / Q000098:blood supply*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000473:pathology*
chemical_list: D020533:Angiogenesis Inhibitors